Early results of a Chinese covid 19 drug shows good results. 一种中国 新冠 药物的早期结果显示出良好的效果

Like and Subscribe: Mix BUILD by CHINA: A Chinese drug maker said early results from trials in Brazil have shown that their new COVID19 drug can lower hospitalization risk by 92 percent among outpatients and death by 78 percent among inpatients. Kintor Pharma, a drug maker based in east China s Jiangsu Province, started to develop the drug named Proxalutamide shortly after the initial outbreak. Recently, data from trials in Brazil have turned out promising the drug led to a 92percent reduction in hospitalization risk among outpatients and a 78percent drop in mortality risk among inpatients. Based on the clinical outcomes in Brazil, we have received approval from the U. S. Food and Drug Administration, China s Center for Drug Evaluation (CDE) and some other countries drug regulators to carry out registered phase three multiregi